(2-苄基异吲哚啉-5-基)甲醇 | 127169-16-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: (2-苄基异吲哚啉-5-基)甲醇
• 英文名称: (2-benzylisoindolin-5-yl)methanol
• 英文别名: 2-benzyl-5-hydroxymethylisoindoline；(2-benzyl-2,3-dihydro-1H-isoindol-5-yl)1-methanol；(2-benzyl-2,3-dihydro-1H-isoindol-5-yl)-methanol；(2-benzyl-1,3-dihydroisoindol-5-yl)methanol
• CAS: 127169-16-8
• 化学式: C₁₆H₁₇NO
• 分子量: 239.317
• InChiKey: OJYMOHXXGCNJGW-UHFFFAOYSA-N

物化性质

• 沸点：
  376.3±37.0 °C(Predicted)
• 密度：
  1.186±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2-苄基异吲哚啉-5-基)甲醇 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 50.0 ℃ 、413.69 kPa 条件下， 反应 30.0h， 以100%的产率得到2,3-二氢-1H-异吲哚-5-基甲醇
  参考文献：
  名称：

  PHARMACEUTICAL COMPOUNDS

  摘要：

  本发明提供了一种用于药物中的化合物，该化合物是式(VI0)的化合物或其盐、溶剂化物、互变异构体或N-氧化物：其中双环基团：选自结构C1、C5和C6：其中n为0、1、2或3；R1为氢、羟基或O—Rz；R2a为羟基、甲氧基或O—Rz；条件是R1和R2a中至少一个是O—Rz；Rz为Lp-Rp1；SO3H；一个葡萄糖苷酸残基；一个单、二或三肽残基；或Lp为键、C═O、(C═O)O、(C═O)NRp1或S(O)xNRp1；x为1或2；Rp1为氢或一个可选地取代的含0、1或2个碳环和0、1、2、3、4、5或6个碳-碳多重键的C1-25烃基团，条件是当Lp为键、C═O或(C═O)O时，Rp1不是氢；并且还条件是O—Rz不包含O—O部分；并排除R1为羟基且R2a为甲氧基的化合物；Rp2和Rp3相同或不同，且各自为Rp1基团；R3、R4a、R8和R10如权利要求中定义。式(VI0)的化合物是其中R1和/或R2a为羟基的母化合物的前药，其中母化合物具有Hsp90抑制活性。

  公开号：

  US20100152184A1
• 作为产物：
  描述：

  3,4-双(溴代甲基)苯甲酸甲酯 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 苯 为溶剂， 生成 (2-苄基异吲哚啉-5-基)甲醇
  参考文献：
  名称：

  Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity

  摘要：

  Some K opioid receptor agonists of the arylacetamide class, for example, ICI 199441 (1), were found to strongly inhibit the activity of cytochrome P450 2D6 (CYP2D6) (1: CYP2D6 IC50 = 26 nM). Certain analogs bearing a substituted sulfonylamino group, for example, 13, were discovered to have significantly reduced CYP2D6 inhibitory activity (13: CYP2D6 IC50 > 10 mu M) while displaying high affinity toward the cloned human K opioid receptor, good kappa/delta and kappa/mu selectivity, and potent in vitro and in vivo agonist activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.020

文献信息

• PHARMACEUTICAL COMPOUNDS
  申请人：Congreve Miles Stuart

  公开号：US20100152184A1

  公开（公告）日：2010-06-17

  The invention provides a compound for use in medicine, the compound being a compound of the formula (VI 0 ) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; R 1 is hydrogen, hydroxy, or O—R z ; R 2a is hydroxy, methoxy or O—R z ; provided that at least one of R 1 and R 2a is O—R z ; R z is L p -R p1 ; SO 3 H; a glucuronide residue; a mono-, di- or tripeptide residue; or L p is a bond, C═O, (C═O)O, (C═O)NR p1 or S(O) x NR p1 ; x is 1 or 2; R p1 is hydrogen or a an optionally substituted C 1-25 hydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that R p1 is not hydrogen when L p is a bond, C═O or (C═O)O; and provided also that O—R z does not contain an O—O moiety; and excluding compounds wherein R 1 is hydroxy and R 2a is methoxy; R p2 and R p3 are the same or different and each is a group R p1 ; and R 3 , R 4a , R 8 and R 10 are defined in the claims. The compounds of formula (VI 0 ) are pro-drugs of parent compounds wherein R 1 and/or R 2a are hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.

  本发明提供了一种用于药物中的化合物，该化合物是式(VI0)的化合物或其盐、溶剂化物、互变异构体或N-氧化物：其中双环基团：选自结构C1、C5和C6：其中n为0、1、2或3；R1为氢、羟基或O—Rz；R2a为羟基、甲氧基或O—Rz；条件是R1和R2a中至少一个是O—Rz；Rz为Lp-Rp1；SO3H；一个葡萄糖苷酸残基；一个单、二或三肽残基；或Lp为键、C═O、(C═O)O、(C═O)NRp1或S(O)xNRp1；x为1或2；Rp1为氢或一个可选地取代的含0、1或2个碳环和0、1、2、3、4、5或6个碳-碳多重键的C1-25烃基团，条件是当Lp为键、C═O或(C═O)O时，Rp1不是氢；并且还条件是O—Rz不包含O—O部分；并排除R1为羟基且R2a为甲氧基的化合物；Rp2和Rp3相同或不同，且各自为Rp1基团；R3、R4a、R8和R10如权利要求中定义。式(VI0)的化合物是其中R1和/或R2a为羟基的母化合物的前药，其中母化合物具有Hsp90抑制活性。
• Isoindoline derivative
  申请人：Wakunaga Seiyaku Kabushiki Kaisha

  公开号：US05026856A1

  公开（公告）日：1991-06-25

  Isoindoline derivatives represented by the formula (I) and their salts are disclosed. ##STR1## There are many varieties for the compound depending on the types of residues R.sup.1 -R.sup.9 and X. The compounds can be prepared from quinoline derivatives of the formula (II) and an isoindoline derivatives of the formula (III). The compounds of formula (I) and their salts have excellent antibacterial activities against both gram positive and gram negative microorganisms. They can be used as a medicine, an agrichemical, and a food preservative.

  公开了由公式（I）表示的异喹啉衍生物及其盐。根据残基R.sup.1-R.sup.9和X的类型，该化合物有许多种类。这些化合物可以由公式（II）的喹啉衍生物和公式（III）的异喹啉衍生物制备而成。公式（I）的化合物及其盐对革兰氏阳性和革兰氏阴性微生物具有出色的抗菌活性。它们可以用作药物、农药和食品防腐剂。
• Benzo-fused compounds for use in treating metabolic disorders
  申请人：Brown Sean P.

  公开号：US20080119511A1

  公开（公告）日：2008-05-22

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一些化合物，可用于治疗受试者的代谢紊乱等疾病。这些化合物的一般式为I，其中变量和A的定义在此提供。本发明还提供了包含这些化合物的组合物，以及使用这些化合物制备药物和治疗代谢紊乱（例如2型糖尿病）的方法。
• HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90
  申请人：Frederickson Martyn

  公开号：US20110046155A1

  公开（公告）日：2011-02-24

  The invention provides an acid addition salt of a compound of the formula (1) Also provided by the invention are processes for preparing the compound of formula (1) and alkyl analogues thereof, novel intermediates for use in the process and methods for preparing the intermediates. The invention also provides new medical uses of compounds of the formula (1) and its ethyl analogue.

  该发明提供了化合物（1）的酸加成盐。该发明还提供了制备化合物（1）及其烷基类似物的方法，用于该过程的新型中间体以及制备中间体的方法。该发明还提供了化合物（1）及其乙基类似物的新医药用途。
• PHARMACEUTICAL COMBINATIONS
  申请人：Gallagher Neil James

  公开号：US20100092474A1

  公开（公告）日：2010-04-15

  The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R 1 is hydroxy or hydrogen; R 2 is hydroxy; methoxy or hydrogen; provided that at least one of R 1 and R 2 is hydroxy; R 3 is selected from hydrogen; halogen; cyano; optionally substituted C 1-5 hydrocarbyl and optionally substituted C 1-5 hydrocarbyloxy; R 4 is selected from hydrogen; a group —(O) n —R 7 where n is 0 or 1 and R 7 is an optionally substituted acyclic C 1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C 1-5 hydrocarbyl-amino; or R 3 and R 4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR 5 R 6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 inhibitors.

  本发明提供的组合物包括（或者基本上由）一种或多种辅助化合物和一个式（I）的化合物组成，或其盐，互变异构体，溶剂化物和N-氧化物；其中R1是羟基或氢原子；R2是羟基，甲氧基或氢原子；至少R1和R2中的一个是羟基；R3选自氢原子，卤素，氰基，可选取代的C1-5烃基和可选取代的C1-5烃氧基；R4选自氢原子，一个—（O）n—R7基团，其中n为0或1，R7是一个可选取代的无环C1-5烃基基团或一个具有3至7个环成员的单环碳环或杂环基团；卤素，氰基，羟基，氨基和可选取代的单一或二元C1-5烃基氨基；或者R3和R4共同形成一个有5至7个环成员的单环碳环或杂环；并且NR5R6形成一个有8至12个环成员的可选取代的双环杂环基团，其中最多有5个环成员是从氧，氮和硫中选取的杂原子。这些组合物具有作为Hsp90抑制剂的活性。